Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine, whether the addition of Sorafenib to
standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results
(event free survival).